Recent Quotes (30 days)

You have no recent quotes
chg | %

Lorus Therapeutics Inc.  

(Public, TSE:LOR)   Watch this stock  
Find more results for LOR
0.450
-0.020 (-4.26%)
Jul 25 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.43 - 0.49
52 week 0.17 - 1.04
Open 0.48
Vol / Avg. 124,518.00/253,177.00
Mkt cap 62.70M
P/E     -
Div/yield     -
EPS -0.17
Shares 139.32M
Beta 0.89
Inst. own     -

Key stats and ratios

Q2 (May '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -87.62% -66.09%
Return on average equity -104.23% -76.31%
Employees 17 -
CDP Score - -

Address

2 Meridian Road
TORONTO, ON M9W 4Z7
Canada
+1-416-7981200 (Phone)
+1-416-7982200 (Fax)

Website links

Description

Lorus Therapeutics Inc. (Lorus) is a life sciences company. The Company is focused on the discovery, research and development of effective anticancer therapies with a safety profile. Lorus has worked to establish a diverse anticancer product pipeline, with products in various stages of development ranging from pre-clinical to a completed Phase I clinical trial. Intellectual property portfolio supports its diverse product pipeline.

Officers and directors

William G. Rice Ph.D. Chairman of the Board, Chief Executive Officer
Gregory K. Chow Chief Financial Officer
Elizabeth Williams Finance Director, IR Contact Officer
Daniel D. Von Hoff M.D., Senior Vice President - Medical Affairs
Yoon Lee PhD Vice President - Research
Jim A. Wright Ph.D. Lead Director
Denis R. Burger Ph.D. Independent Director
Age: 69
Brad Thompson Independent Director
Brian J. Underdown Ph.D. Independent Director
Age: 72
Mark D. Vincent M.D. Independent Director